Application of jellyfish collagen
By using jellyfish collagen compositions extracted and treated from jellyfish, the problems of poor angiogenesis and high transmission risk in existing wound healing materials are solved, achieving more effective wound healing effects, especially in the treatment of chronic wounds Shows superior healing ability.
Patent Information
- Application Number
- CN202411312788.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-04-07
- Filing Date
- 2021-04-07
- Publication Date
- 2024-11-22
AI Technical Summary
Among the existing wound healing materials, mammalian collagen-based products have problems such as poor angiogenic characteristics, increased risk of disease and virus transmission, and high costs, making it difficult to effectively promote chronic wound healing.
Using jellyfish collagen as a substitute for wound healing materials, different forms of jellyfish collagen compositions such as determinated peptides, thiolated or crosslinked jellyfish collagen, by extracting and purifying acid-soluble collagen from jellyfish, using for treating wounds.
Jellyfish collagen compositions show superior angiogenic properties, low immunogenicity and low risk of viral transmission, which can effectively promote wound healing, especially in the treatment of chronic wounds such as diabetic foot ulcers.
Smart Images

Figure BDA0005051172980000121 
Figure BDA0005051172980000133 
Figure BDA0005051172980000141
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 202180029377.8, application date April 7, 2021, and invention name “Uses of jellyfish collagen”. Technical Field
[0002] The present invention relates to jellyfish collagen for treating wounds and its preparation. Background Art
[0003] Wound healing is a complex process involving coordinated interactions between different immune and biological systems. Chronic wounds remain a challenging clinical problem affecting approximately 6 million patients per year with high economic impact.
[0004] Wound healing is the process by which the skin (or another organ or tissue) repairs itself after an injury. In normal skin, the epidermis (outermost layer) and dermis (inner or deeper layers) are in a steady-state equilibrium and are isolated from the outside world. When the skin is broken, the normal (physiological) process of wound healing begins. The classic model of wound healing consists of three or four sequential and overlapping phases:
[0005] Phase 1: Stop the bleeding.
[0006] Stage 2: Inflammation.
[0007] Stage 3: Hyperplasia.
[0008] Phase 4: Remodeling.
[0009] After skin injury, a complex series of biochemical events occur in a tightly coordinated cascade to repair the damage. Due to many potential stimuli (local tissue ischemia, bioburden, necrotic tissue, repeated trauma, etc.), wounds may stagnate in the inflammatory phase, leading to chronicity of the wound. A key component of chronic wounds is the elevated levels of matrix metalloproteinases (MMPs). At elevated levels, MMPs not only degrade non-viable collagen, but also degrade viable collagen. In addition, fibroblasts in chronic wounds may not secrete sufficient levels of MMP tissue inhibitors (TIMPs) to control the activity of MMPs. These events prevent the formation of scaffolds required for cell migration and ultimately prevent the formation of extracellular matrix (ECM) and granulation tissue. In the case of chronic wounds, including diabetic foot ulcers, the combination of associated chronic microbial infection and inflammation may lead to capillary degeneration (reduced blood flow) and amputation. Therefore, new drugs targeting diabetic foot ulcers (DFUs) can advantageously provide the ability to stimulate blood flow to the affected area and promote wound healing.
[0010] Collagen-based wound dressings have been shown to be particularly suitable for addressing the problem of elevated MMP levels by acting as a 'sacrificial matrix' in the wound. Collagen breakdown products have also been shown to be chemotactic for a variety of cell types required for the formation of granulation tissue. Additionally, collagen-based dressings have the ability to absorb wound exudate and maintain a moist wound environment.
[0011] Many different collagen dressings are available, using various carriers / composition agents such as gels, pastes, polymers, oxidized regenerated cellulose (ORC), and ethylenediaminetetraacetic acid (EDTA). The collagen in these products is often derived from bovine, porcine, equine, or avian sources, which are purified to render them non-antigenic. However, there are a number of disadvantages associated with the use of these collagen types, including poor angiogenic properties, increased risk of disease and viral transmission, and considerable costs associated with obtaining these collagens.
[0012] Therefore, it would be particularly advantageous to have a source of collagen suitable for use in treating wounds without exhibiting the above-mentioned disadvantages. Summary of the invention
[0013] The present invention relates to jellyfish collagen for use in treating wounds. As will be apparent from the in vivo and in vitro data presented below, the inventors surprisingly discovered that compositions comprising jellyfish collagen can be used as a substitute for mammalian collagen (e.g., bovine) for treating wounds while showing equivalent results and providing many superior qualities, such as angiogenic properties, increased stability, low immunogenicity, and lower risk of viral and disease / prion transmission. This is a completely unexpected discovery given the vastly different physicochemical and amino acid properties of jellyfish collagen compared to mammalian collagen.
[0014] Thus, a first aspect of the present invention relates to a composition for treating a wound, wherein the composition comprises jellyfish collagen.
[0015] The second aspect of the present invention relates to a method for producing the above-mentioned jellyfish collagen, which at least comprises the following steps:
[0016] i) extracting acid-soluble collagen from a jellyfish collagen source; and
[0017] ii) purifying the jellyfish collagen to provide a purified jellyfish collagen solution. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Embodiments of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
[0019] Figure 1Shown is the change in group mean width (mm) from day 3 to day 7, as determined by caliper measurements.
[0020] Figure 2 Shown is the change in group mean width (mm) from day 3 to day 7, as determined by morphometry.
[0021] Figure 3 The change in group mean epithelial regeneration (%) from day 3 to day 7 is shown.
[0022] Figure 4 Shown are the changes in group mean tissue granulation scores (4A) and mean percentage (%) of wound area granulation (4B) from day 3 to day 7.
[0023] Figure 5 Representative images of H&E stained wound sections of the Tegaderm only group are shown. Panels A), B) and C) represent images collected from wound sections on day 3, and panels D), E) and f) represent images collected from wound sections on day 7.
[0024] Figure 6 Representative images of H&E stained wound sections of the jellyfish collagen sponge group are shown. Panels A), B) and C) represent images collected from wound sections on day 3, and panels D), E) and f) represent images collected from wound sections on day 7.
[0025] Figure 7 Representative images of H&E stained wound sections from the chemically modified (thiolated) jellyfish collagen paste group are shown. Panels A), B) and C) represent images collected from wound sections on day 3, and panels D), E) and f) represent images collected from wound sections on day 7.
[0026] Figure 8 Representative images of H&E stained wound sections of the cross-linked jellyfish collagen sponge group are shown. Panels A), B) and C) represent images collected from wound sections on day 3, and panels D), E) and f) represent images collected from wound sections on day 7.
[0027] Fig. 9 Shows Representative images of H&E stained wound sections of the group. Panels A), B) and C) represent images collected from wound sections on day 3, and panels D), E) and f) represent images collected from wound sections on day 7.
[0028] Fig.10Representative images of collagen I-stained wound sections from different treatment groups on days 3 and 7 are shown. Figure A) shows wound sections of the Tegaderm group on day 3, Figure B) shows wound sections of the Tegaderm group on day 7, Figure C) shows wound sections of the jellyfish collagen sponge group on day 3, Figure D) shows wound sections of the jellyfish collagen sponge group on day 7, Figure E) shows wound sections of the chemically modified (thiolated) jellyfish collagen paste group on day 3, Figure F) shows wound sections of the chemically modified (thiolated) collagen paste group on day 7, Figure G) shows wound sections of the cross-linked jellyfish collagen sponge group on day 3, Figure H) shows wound sections of the cross-linked jellyfish collagen sponge group on day 7, Figure I) shows Group 3 wound sections on day 3, and Figure L) shows Wound sections were taken in each group on the 7th day.
[0029] Fig.11 Shown are representative images of wound sections from the Tegaderm only group (day 3), labeled with the specific endothelial cell marker CD31.
[0030] Fig.12 Shown are representative images of wound sections from the Tegaderm only group (day 7), labeled with the specific endothelial cell marker CD31.
[0031] Fig.13 Shown are representative images of wound sections of the jellyfish collagen sponge group (day 3), labeled with the specific endothelial cell marker CD31.
[0032] Fig.14 Shown are representative images of wound sections of the jellyfish collagen sponge group (day 7), labeled with the specific endothelial cell marker CD31.
[0033] Fig.15 Representative images of wound sections of the chemically modified (thiolated) jellyfish collagen paste group (day 3) are shown, labeled with the specific endothelial cell marker CD31.
[0034] Fig.16 Representative images of wound sections of the chemically modified (thiolated) jellyfish collagen paste group (day 7) are shown, labeled with the specific endothelial cell marker CD31.
[0035] Fig.17 Shown are representative images of wound sections of the cross-linked jellyfish collagen sponge group (day 3), labeled with the specific endothelial cell marker CD31.
[0036] Fig.18Shown are representative images of wound sections of the cross-linked jellyfish collagen sponge group (day 7), labeled with the specific endothelial cell marker CD31.
[0037] Fig.19 Shows Representative images of wound sections from the 1:1 group (day 3) labeled with the specific endothelial cell marker CD31.
[0038] Fig. 20 Shows Representative images of wound sections from the 1:1 group (day 7) labeled with the specific endothelial cell marker CD31.
[0039] Fig.21 The wound closure curves of the treatment groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model are shown as "% wound area remaining over time". The experiment was performed as described in Example 3, and the test groups were: control (film dressing only); non-crosslinked sponge; 0.5% EDC XL powder; 1.0% EDC XL powder; Promogran TM ).
[0040] Fig. 22 The wound contraction curves of the treated groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model are shown as "% wound contraction". The experiment was performed as described in Example 3, and the test groups were: control (film dressing only); non-crosslinked sponge; 0.5% EDC XL powder; 1.0% EDC XL powder; Promogran TM ).
[0041] Fig.23 The epithelial regeneration curve of the wound is shown as "% wound epithelial regeneration", which was first measurable on day 4 after injury between different treatment groups in the db / db (BKS.CG-mDock 7m+ / _+Leprdb / J) diabetic mouse model. The experiment was performed as described in Example 3, and the test groups were: control (film dressing only); non-crosslinked sponge; 0.5% EDC XL powder; 1.0% EDC XL powder; Promogran TM ).
[0042] Fig.24 Representative examples (approximately to scale) of the histological appearance of wounds in each experimental group in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model are shown. Fig.25 Higher magnification views of the central area of each wound can be found in .
[0043] Fig.25 Shows Fig.24 Higher magnification images of the central area of a representative example of the histological appearance of a wound are shown in FIG.
[0044] Fig.26 Shown are the effects of 1% EDC cross-linked jellyfish collagen powder on: (A) Day 8; (B) Day 12; and (C) Day 16, showing progressive vascularization of the hydrated mass (V).
[0045] Fig. 27 The wound closure curves for all treatment groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model are shown as "% wound area remaining over time". The experiment was performed as described in Example 4, and the test groups were: control (film dressing only); 1.0% EDC XL powder; thiolated powder; Flowable matrix. Results are shown for all animals in the test group - mean ± sem (n = 12 to day 35, n = 4, day 42 to day 63).
[0046] Fig.28 The data as "% wound area remaining over time" show the wound closure curves for all tested jellyfish collagen treatment groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model. The experiment was performed as described in Example 4. The results for all animals in the test group are shown - mean ± sem (n = 12 to day 35).
[0047] Fig.29 The data as "% wound area remaining over time" show the wound closure curves of the thiolated powder and Integra FM treated groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model. The experiment was performed as described in Example 4. The results for all animals in the test group are shown - mean ± sem (n = 12 to day 35).
[0048] Fig.30 The wound contraction curves of the treated groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model are shown as "% Wound Contraction". The experiment was performed as described in Example 4, and the test groups were: control (film dressing only); XL sponge; 1.0% EDC XL powder; thiolated powder; Flowable matrix. Results are shown for all animals in the test group - mean ± sem (n = 12 to day 35, n = 4, day 42 to day 63).
[0049] Fig.31 The data "% wound contraction" shows the wound contraction curves of all tested aequorea collagen treated groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model. The experiment was performed as described in Example 4. The results of all animals in the test group are shown - mean ± sem (n = 12 to day 35).
[0050] Fig.32 The data "% Wound Contraction" shows the wound contraction curves of the thiolated powder and Integra FM treated groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model. The experiment was performed as described in Example 4. The results of all animals in the test group are shown - mean ± sem (n = 12 to day 35).
[0051] Fig.33 The epithelial regeneration curve of the wound is shown as "% Wound Epithelial Regeneration", which was first measurable on day 4 after injury between different treatment groups in the db / db (BKS.CG-mDock 7m+ / _+Leprdb / J) diabetic mouse model. The experiment was performed as described in Example 4, and the test groups were: control (film dressing only); 1.0% EDC XL powder; thiolated powder; Flowable matrix. Results are shown for all animals in the test group - mean ± sem (n = 12 to day 35, n = 4, day 42 to day 63).
[0052] Fig.34 The epithelial regeneration curves of wounds of all tested jellyfish collagen treated groups are shown as "% wound epithelial regeneration" first measurable at day 4 after wounding between different treatment groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model. The experiments were performed as described in Example 4. Results for all animals in the test group are shown - mean ± sem (n = 12 to day 35).
[0053] Fig.35 The epithelial regeneration curves of the wounds of the tested thiolated powder and Integra FM treated groups are shown as "% Wound Epithelial Regeneration" first measurable at day 4 after wounding between the different treatment groups in the db / db (BKS.CG-m Dock 7m+ / _+Leprdb / J) diabetic mouse model. The experiments were performed as described in Example 4. The results for all animals in the tested groups are shown - mean ± sem (n = 12 to day 35). DETAILED DESCRIPTION
[0054] In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. One of ordinary skill in the art will appreciate that embodiments of the present invention may be practiced without these specific details while still remaining within the scope of the claims.
[0055] In a first aspect, the present invention provides a composition for treating a wound, wherein the composition comprises jellyfish collagen.
[0056] The phrase 'treatment of wounds' or the term 'wound therapy' refers to any treatment that aids in the complex process by which the skin and any associated tissues repair themselves following injury. Examples of wounds that may benefit from the use of jellyfish collagen include, but are not limited to, pressure sores, graft sites, surgical wounds, ulcers, burns (thermal, chemical or electrical), lacerations, abrasions, puncture wounds, avulsions, seromas and / or hematomas. In a preferred embodiment, the wound is not associated with Epidermolysis Bullosa.
[0057] In some embodiments, the jellyfish collagen is not in a hydrolysate form. By "hydrolysate form" is meant collagen that has been degraded by heat or protease / collagenase activity to produce collagen fragments defined as collagen peptides and gelatin-like molecules.
[0058] The jellyfish collagen used to treat wounds may be in its telopeptide form. By "telopeptide form" is meant a low immunogenic derivative of collagen obtained by removing the N-terminal and C-terminal telopeptide components known to induce antigenicity in humans. The telopeptides are typically removed by treating collagen with type I pepsin.
[0059] The jellyfish collagen used for wound treatment may be in the telopeptide form thereof. The term "telopeptide form" means that collagen extracted under acidic conditions produces soluble collagen containing telopeptides.
[0060] The jellyfish collagen used to treat wounds may be thiolated. The term 'thiolated' refers to the reaction of jellyfish collagen with thiols, resulting in the introduction of -SH groups or 'thiol' groups.
[0061] The jellyfish collagen used to treat wounds can be cross-linked. In the context of the present invention, the term 'cross-linked' refers to two independent collagen molecules connected by covalent bonds. Preferably, the collagen molecules to be cross-linked are in the form of collagen fibers, resulting in cross-linking between fibrils. In order to produce cross-linked thiolated jellyfish collagen, a 'cross-linking agent' ('cross-linking agent' or 'cross-linker') can be used. The term 'cross-linking agent' ('cross-linkingagent' or 'cross-linker') refers to a reagent that can form a covalent connection between two independent molecules under certain conditions. In the context of the present invention, a cross-linking agent is used to covalently connect two independent collagen molecules. Preferably, the collagen molecules to be cross-linked are in the form of collagen fibers. Preferably, cross-linking between fibrils occurs. In some cases, the cross-linking agent is generally composed of two or more reactive functional groups connected together by a hydrocarbon chain. Two or more functional groups do not necessarily have to be the same. The length of the hydrocarbon chain can also be changed to control the distance between the functional groups. The exact length of the hydrocarbon chain in the context of the present invention is not intended to be limited.
[0062] Jellyfish collagen used to treat wounds can be non-cross-linked.
[0063] The source of jellyfish collagen can be from the Scyphozoa subphylum. The source of jellyfish collagen for treating wounds can be selected from the group consisting of: Rhizostomeae order, including but not limited to brown Rhizostomas pulmo, Rhopilema esculentum, Rhopilema nomadica, Stomolophus meleagris, Cassiope asp. (fairy jellyfish), including but not limited to Cassiopea andromeda, Semaeostomease order, including Aurelia asp. and other genera, such as Nemopilemanomurai, sand jellyfish, Mediterranean jellyfish, Stomolophus meleagris or any combination thereof. Preferably, the source of jellyfish collagen is brown Rhizostomeae. Thus, the collagen may include at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% brown rhizopus collagen.
[0064] The jellyfish collagen used to treat wounds can have a concentration of at least 1 mg / mL. It is envisioned that the maximum concentration of jellyfish collagen that can be used is 50 mg / mL. Thus, the concentration of jellyfish collagen can be between 1 mg / mL and 50 mg / mL, 2 mg / mL and 50 mg / mL, 3 mg / mL and 50 mg / mL, 4 mg / mL and 50 mg / mL, 5 mg / mL and 50 mg / mL, 6 mg / mL and 50 mg / mL, 7 mg / mL and 50 mg / mL, 8 mg / mL and 50 mg / mL, 9 mg / mL and 50 mg / mL, 10 mg / mL and 50 mg / mL, 11 mg / mL and 50 mg / mL, 12 mg / mL and 50 mg / mL, 13 mg / mL and 14 mg / mL and 15 mg / mL. L to 50 mg / mL, 14 mg / mL to 50 mg / mL, 15 mg / mL to 50 mg / mL, 16 mg / mL to 50 mg / mL, 17 mg / mL to 50 mg / mL, 18 mg / mL to 50 mg / mL, 19 mg / mL to 50 mg / mL, 20 mg / mL to 50 mg / mL, 25 mg / mL to 50 mg / mL, 30 mg / mL to 50 mg / mL, 35 mg / mL to 50 mg / mL, 40 mg / mL to 50 mg / mL, or 45 mg / mL to 50 mg / mL.
[0065] The jellyfish collagen used to treat wounds can remain stable at temperatures up to at least 37°C. The term 'stable' refers to the ability of the jellyfish collagen to remain substantially unaltered and maintain its desired properties under given environmental conditions. This is an advantageous property given that the intended use of the invention involves physical contact of the product with a subject. It is envisaged that the subject is a human, however the invention can also be used in the veterinary industry, for example for wound treatment of dogs, cats, horses, cattle, goats, sheep, etc.
[0066] The jellyfish collagen for treating wounds may be in the form of a hydrogel, a paste, a powder, preferably a micronized powder, a film, a scaffold, a solution, a sponge matrix, a nanofiber electrospun matrix, or in a lyophilized form.
[0067] A 'hydrogel' is a hydrophilic network of polymer chains that creates a highly water-absorbent material. The term 'paste' refers to a semi-solid preparation, usually intended for topical application to the skin. Typically, when used in a pharmaceutical formulation, it consists of a fatty base (e.g., petrolatum) and is at least 25% solid matter (e.g., zinc oxide). The skilled person will recognize that the form of jellyfish collagen selected may depend on the specific wound to be treated. For example, a burn may require a hydrogel or fine collagen mesh formulation.
[0068] Compositions for use according to the present invention may include additional active pharmaceutical ingredients. Additional active pharmaceutical ingredients include growth factors, anti-inflammatory agents and antimicrobial drugs. Examples of anti-inflammatory agents may include nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin salsalate, diflunisal, ibuprofen, ketoprofen, nabumetone, piroxicam, naproxen, diclofenac, indomethacin and sulindac. The concentration of the selected anti-inflammatory drug should be understood to depend on the type and severity of the wound to be treated. Examples of antimicrobial agents that can be used include but are not limited to nano silver, penicillin, ofloxacin, tetracycline, aminoglycosides and erythromycin. Mixtures of two or more of the above-mentioned pharmaceutically active ingredients are contemplated, with or without the excipients and carriers listed above.
[0069] In some embodiments, the composition for use according to the present invention further includes at least one growth factor. In a preferred embodiment, the at least one growth factor is platelet-rich plasma (PRP), epithelial growth factor 38 (EGF), transforming growth factor-β (TGF-B, TGF-B2, TGF-B3), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), granulocyte-monocyte colony stimulating growth factor, platelet-derived growth factor, insulin-like growth factor 1 (IGF1), basic fibroblast growth factor (bFGF) and / or vascular endothelial growth factor 5 (VEGF) or any combination thereof.
[0070] The composition for use according to the present invention may further include at least one antimicrobial compound. Preferably, the at least one antimicrobial compound is nanosilver, penicillin, ofloxacin, tetracycline, aminoglycosides and erythromycin, flucloxacillin, clarithromycin, doxycycline, gentamicin, metronidazole, co-amoxiclav, co-trimoxazole (in penicillin), ceftriaxone, piperacillin and tazobactam, clindamycin, ciprofloxacin, vancomycin, teicoplanin, linezolid and / or standard of care antimicrobial agents or any combination thereof.
[0071] The composition for treating wounds can be formulated for topical application to the wound. In the context of the present invention, the term 'topical application' is intended to refer to the application of jellyfish collagen to a specific part of the wound to be treated. The wound to be treated may be present on the skin of the subject or on the mucous membrane of the subject, such as inside the oral cavity. The composition for use according to the present invention can be formulated for administration by any other route known in the art. For example, the composition for use according to the present invention can be formulated for administration by negative pressure wound therapy (NPWT) (also known as vacuum assisted closure (VAC)), which involves the use of a sealed wound dressing connected to a vacuum pump to control the application of a pressure below atmospheric pressure to the local wound environment.
[0072] In some embodiments, the composition for use according to the present invention comprises a dosage of 0.01 g / L to 200 g / L, preferably 1 g / L to 50 g / L of collagen per application.
[0073] The composition for use according to the invention can be formulated as a cream, a double gel, an ointment, a mask, a serum, a milk, a lotion, a paste, a foam, an aerosol, a stick, a shampoo, a conditioner, a patch, a hydroalcoholic or oily aqueous solution, an oil-in-water or water-in-oil or multiple emulsions, an aqueous or oily gel, a liquid, a paste or a solid anhydrous product, an electrospun collagen nanofibrous matrix, a membrane and / or an oil dispersion using spheres in an aqueous phase, which are polymer nanoparticles, such as nanospheres and nanocapsules or lipid vesicles of ionic and / or non-ionic type, more preferably an electrospun collagen nanofibrous matrix and / or a membrane.
[0074] The composition comprising jellyfish collagen for use according to the present invention may further include a pharmaceutically acceptable excipient and / or carrier, and / or a pharmaceutically active ingredient. Excipients and carriers can enhance the stability of the pharmaceutically active ingredient or jellyfish collagen and / or improve the biopharmaceutical properties of the pharmaceutically active ingredient or jellyfish collagen, which may or may not have a conjugated active substance. Examples of suitable pharmaceutically acceptable excipients and carriers may include sterile water, olive oil, ethyl oleate, ethylene glycol, monosaccharides such as fructose, glucose and galactose; non-reducing disaccharides such as sucrose, lactose and trehalose; non-reducing oligosaccharides such as raffinose and melezitose; non-reducing starch-derived polysaccharide products such as maltodextrin, dextran and cyclodextrin; and non-reducing sugar alcohols such as mannitol and xylitol. Other suitable excipients include cellulose preparations such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth and / or polyvinylpyrrolidone. Mixtures of two or more of the above excipients or carriers (or any other suitable equivalents) are also contemplated. It should be understood that any other substance with a similar effect will also be suitable.
[0075] In a preferred embodiment, the pharmaceutical active ingredient can be 1% lidocaine. Lidocaine or lidocaine hydrochloride is an anesthetic, commonly used as a numbing agent. Lidocaine can be up to 5% lidocaine, such as lidocaine between 0.1% and 5%, lidocaine between 0.5% and 5%, lidocaine between 1% and 5%, lidocaine between 1.5% and 5%, lidocaine between 2% and 5%, lidocaine between 2.5% and 5%, lidocaine between 3% and 5%, lidocaine between 3.5% and 5%, lidocaine between 4% and 5%, and lidocaine between 4.5% and 5%. Preferably, the concentration of lidocaine is 0.1% to 2%. Examples of additional anesthetics suitable for the same purpose include, but are not limited to, benzocaine, butamben, dibucaine, lidocaine, oxybuprocaine, pramoxine, proparacaine, proxymetacaine, and tetracaine.
[0076] The composition for use according to the invention can be used to treat a wound selected from the list consisting of: pressure sores, graft sites, surgical wounds, ulcers, preferably diabetic ulcers, thermal burns, chemical burns, electrical burns, lacerations, abrasions, puncture wounds, avulsions, seromas and / or hematomas.
[0077] It is envisaged that the present invention may constitute at least part of a wound dressing, with or without the additional presence of the above-mentioned agents.Wound dressings may contain additional ingredients, such as alginates and cellulose derivatives, which may enhance absorbency, flexibility and comfort, and help maintain an environment conducive to healing.
[0078] In one embodiment, the composition for use according to the present invention may include jellyfish collagen in the form of micronized powder. Preferably, the micronized powder has a particle size of 1 μm to 1000 μm, more preferably, the micronized powder has a particle size of 200 μm to 500 μm.
[0079] In certain embodiments, a composition for use according to the present invention may include jellyfish collagen in the form of a collagen 3D sponge scaffold.
[0080] In some embodiments, the compositions for use according to the invention promote improved angiogenesis in treated wounds. Preferably, the improved angiogenesis is relative to untreated wounds and / or wounds treated with bovine collagen.
[0081] In a second aspect of the present invention, a method for producing the above-mentioned jellyfish collagen comprises at least the following steps:
[0082] i) extracting acid-soluble collagen from a jellyfish collagen source; and
[0083] ii) purifying the jellyfish collagen to provide a purified jellyfish collagen solution.
[0084] 'Purified jellyfish collagen solution' refers to an isolated jellyfish collagen solution that is substantially monomeric, or alternatively substantially free of collagen fibrils. In this context, 'substantially free' means that less than 2% by weight of collagen in the collagen solution is composed of fibrils. In order to maintain the collagen solution under these conditions, the isolated collagen can be stored under conditions that are not conducive to the formation of collagen fibrils. This can mean that the collagen is stored under acidic conditions, wherein acidic means any solution whose pH is pH 1 to pH 6.5, or alternatively under alkaline conditions, wherein alkaline means any solution whose pH is pH 8 to pH 14. As a non-limiting example, collagen can be stored in a 0.1M weak acid solution. The weak acid can be acetic acid or hydrochloric acid. The collagen concentration in the collagen solution can be in the range of 0.1mg / ml to 30mg / ml. Preferably, the concentration of the collagen solution is 1mg / ml to 10mg / ml.
[0085] There are a variety of methods to 'isolate' or 'purify' jellyfish collagen from the anatomical environment. Many of these are well known and conventional to the skilled person. For example, collagen can be purified from jellyfish by acid extraction, wherein different anatomical parts of the jellyfish are bathed in an acidic solution. 'Bathing' or 'bathed' refers to the process of incubating the jellyfish in an acidic solution for a sufficient amount of time to release the collagen molecules. An alternative method for collagen purification is enzymatic extraction, wherein the jellyfish is incubated with at least one proteolytic enzyme for a sufficient amount of time and under conditions that are conducive to degradation of the anatomical environment to release the collagen molecules. The exact temperature, pH and incubation time of the enzymatic extraction method will vary depending on the proteolytic enzyme used. The most suitable conditions are well known to the skilled person. As a non-limiting example, the enzyme pepsin can be incubated with the jellyfish under acidic conditions to release the collagen molecules. It is contemplated that any enzyme can be used in the enzymatic extraction method, and the above examples are by no means intended to be limiting.
[0086] The collagen can then be further separated or purified from the undesirable contaminants of the acid or enzyme extraction process in many different ways. For example, insoluble contaminants can be removed by centrifugation. If a purer source of collagen is needed, the separated collagen can be subjected to gel filtration, or alternative chromatography methods that can purify the collagen molecules can be used to remove other soluble contaminants in the extraction process. The exact method of further purification is not particularly limited. Any method known to protein biochemists and routinely used can be used to obtain purified or separated jellyfish collagen. This step can also transfer the jellyfish collagen to the desired storage buffer to obtain the desired purified jellyfish collagen solution. This can be achieved by first balancing the chromatographic equipment with the desired storage buffer before purification. There are many alternative, well-known methods that can be used for this purpose. Preferably, the purity of the collagen solution used for the present invention is 70% to 99%, wherein purity refers to the weight % attributable to the collagen molecules in the solution. More preferably, the purity of the collagen solution is at least 95%, 96%, 97%, 98% or 99%.
[0087] In some embodiments, the manufacturing method further comprises the following steps:
[0088] iii). Adding a cross-linking agent to form cross-linked jellyfish collagen.
[0089] In some embodiments, the cross-linking agent is EDC, genipin or polyethylene glycol (PEG). Preferably, the cross-linking agent is EDC. The concentration of EDC can be 0.01% to 5%, 0.05% to 5%, 0.1% to 5%, 0.2% to 5%, 0.3% to 5%, 0.4% to 5%, 0.5% to 5%, 0.6% to 5%, 0.7% to 5%, 0.8% to 5%, 0.9% to 5%, 1% to 5%, 1.5% to 5%, 2% to 5%, 3% to 5%, 3.5% to 5%, 4% to 5% or 4.5% to 5%. Preferably, the concentration of EDC is 0.5% to 1%.
[0090] In some embodiments, the method of making jellyfish collagen further comprises digesting the extracted jellyfish collagen with a peptidase to provide atelo-jellyfish collagen. Preferably, in the step of digesting the collagen with a peptidase, the peptidase is pepsin. Pepsin can be mammalian, non-mammalian (e.g., papain) or microbial. In some embodiments, the step of digesting the collagen with a peptidase is after the extraction step and before the purification step.
[0091] The method for producing the jellyfish collagen may further include the following steps: i) providing jellyfish collagen including SS bonds; ii) introducing -SH groups into the jellyfish collagen including SS bonds by reducing the SS bonds to provide collagen thiol including -SH groups.
[0092] In order for the jellyfish collagen to include -SH groups, the jellyfish collagen must first include SS bonds or 'disulfide' groups. Naturally occurring collagen does not typically include SS bonds. Disulfide groups can be incorporated into collagen by a variety of means. Jellyfish collagen including SS bonds can be obtained by jellyfish collagen having one or both of lysine and hydroxylysine residues. Collagen is formed by a triple helix of polypeptide chains, one or more of which typically include one or both of lysine and hydroxylysine residues. Lysine and hydroxylysine are α-amino acids with ε-amino groups. As used herein, the term 'residue' refers to the portion of a compound remaining after incorporation (e.g., by chemical reaction and bond formation) of another substance. Thus, an amino acid 'residue' refers to the polymerized form of an amino acid monomer present in a polypeptide. Although the content in collagen is 4 to 5 times less than that of lysine residues, the content of hydroxylysine residues is also sufficient for use in the methods disclosed herein. Thus, collagen including lysine or hydroxylysine residues, prior to treatment as described herein, may include residues of formula (XI):
[0093]
[0094] Where R 5 is H or OH. When R5 When R is H, a lysine residue is present. 5 is OH, a hydroxylysine residue is present; and
[0095] X is selected from the group OH and a chemical bond, and Y is selected from H and a chemical bond, provided that one or both of X and Y are chemical bonds that form peptide bonds within collagen. The peptide chain that forms part of the modified collagen is enclosed in "[]" in formula (XI). The residue may be in a terminal position of the peptide, for example if one or the other of X and Y is OH and H, respectively. If both X and Y are peptide bonds, the lysine residue is non-terminal in the peptide chain, forming part of the collagen.
[0096] The jellyfish collagen comprising one or both of lysine and hydroxylysine residues is preferably a solubilized jellyfish collagen comprising one or both of lysine and hydroxylysine. Solubilization may be achieved by pepsin digestion or acid digestion to provide pepsin-solubilized jellyfish collagen comprising one or both of lysine and hydroxylysine or by acid digestion to provide acid-solubilized jellyfish collagen comprising one or both of lysine and hydroxylysine.
[0097] Aequorea collagen, such as pepsin-solubilized or acid-solubilized aequorea collagen, comprising one or both of lysine and hydroxylysine residues, can be reacted with an activated dicarboxylic acid derivative comprising a disulfide (i.e., SS) group to provide a collagen comprising an SS bond. In this reaction, the carbonyl group of the activated dicarboxylic acid derivative can react with the ε-amino group of the lysine or hydroxylysine residue present in the aequorea collagen to form an amide bond.
[0098] The activated dicarboxylic acid derivative is preferably a compound of the formula:
[0099] ZN-C(O)-R 3 -C(O)-NH-R 1 -SSR 2 -NH-C(O)-R 3 -C(O)-NZ(I)
[0100] Where R 1 , R 2 and R 3 R independently represents a divalent linking group, preferably a divalent organic linking group, more preferably a divalent hydrocarbon linking group, such as an alkanediyl group having 1 to 6 carbon atoms or an alkenediyl group or an alkynediyl group having 2 to 6 carbon atoms. Still more preferably, R 1 , R 2 and R 3 independently represents ethylenediyl or propylenediyl, most preferably ethylenediyl, i.e. -CH 2 CH 2-. Group R 1 , R 2 and R 3 Can be optionally substituted by replacing one to four hydrogen atoms with hydroxyl or halogen (such as F or Cl). In a preferred embodiment, R 1 and R 2 The same; ZN and ZN together represent a nitrogen-containing heterocyclic radical, preferably a nitrogen-containing heterocyclic radical having 5 to 6 atoms in the heterocyclic ring, wherein the N atom is directly bonded to the carbonyl group of the compound of formula (I), so that Z represents a divalent linking group, wherein two valencies are bonded to the nitrogen. The heterocyclic radical may be saturated or unsaturated, so that Z may represent an alkanediyl, an alkenediyl or an alkynediyl, in particular having 2 to 4 carbon atoms. Z may optionally include 1 or 2 heteroatoms selected from O, S and N.
[0101] More preferably, ZN is a nitrogen-containing heteroaryl having 5 to 6 atoms in the aromatic ring, of which 1 to 3 atoms are heteroatoms selected from O, N and S, of which at least 1 is N directly bonded to the carbonyl group of the compound of formula (I). Still more preferably, the heteroaryl has 5 to 6 atoms in the aromatic ring, of which 2 atoms are N. Alternatively, ZN is a nitrogen-containing heterocyclic group having 5 to 6 atoms in a heterocyclic ring having 1 N atom, which is directly bonded to the carbonyl group of the compound of formula (I), and Z is an α,ω-organic diketone diradical. For example, an α,ω-organic diketone diradical can be represented as –C(O)R 4 C(O)-, where R 4 It is an alkanediyl or alkenediyl group having 2 or 3 carbon atoms.
[0102] The group ZN may optionally be substituted by replacing one to four hydrogen atoms with a hydroxyl group or a halogen such as F, Br or Cl or by replacing two hydrogen atoms bonded to the same carbon with an oxygen atom to form a carbonyl group, wherein the latter substitution may occur once or twice.
[0103] Most preferably, the group ZN is:
[0104] 1-imidazole, i.e. or 1-pyrrolidine-2,5-dione, i.e.
[0105] Preferred activated dicarboxylic acid derivatives may be selected from:
[0106]
[0107] The activated dicarboxylic acid derivative (I) can be synthesized in two steps. First, a diaminodisulfide of formula (IV) can be reacted with at least two molar equivalents of a dicarboxylic anhydride of formula (V) to provide a dicarboxylic acid diamide of formula (VI):
[0108]
[0109] Where R 1 , R 2 and R 3 is defined as above. Obviously, when R 1 and R 2 At the same time, the diaminodisulfide of formula (IV) is a symmetrical molecule, which will produce a symmetrical activated dicarboxylic acid derivative (I).
[0110] The first reaction step can be carried out by dissolving the diaminodisulfide of formula (IV) in a solvent such as water and adding the dicarboxylic anhydride of formula (V). Preferably, the reaction is carried out under alkaline conditions, so that before adding the anhydride, a base can be added. For example, an aqueous sodium hydroxide solution can be added to adjust the pH to 10. After adding the dicarboxylic anhydride, the pH may be reduced, preferably by adding additional base during the reaction to maintain the pH in the range of 7 to 10. The reaction can be carried out at room temperature with stirring and can be completed within 30 minutes to 2 hours. The dicarboxylic acid diamide product of formula (VI) can be precipitated by adding an acid (such as an aqueous hydrochloric acid solution) to reduce the pH, for example, to a pH of 1. The precipitated dicarboxylic acid diamide (VI) can be separated by filtering, washing with water, and then drying under reduced pressure.
[0111] In the second step of the synthesis, the dicarboxylic acid diamide (VI) is activated by adding a nitrogen-containing heterocyclic compound to provide an activated dicarboxylic acid derivative (I):
[0112] HO-C(O)-R 3 -C(O)-NH-R 1 -SSR 2 -NH-C(O)-R 3 -C(O)-OH(VI)→
[0113] ZN-C(O)-R 3 -C(O)-NH-R 1 -SSR 2 -NH-C(O)-R 3 -C(O)-NZ(I)
[0114] Where R 1 , R 2 , R 3 and NZ are as defined above.
[0115] In one embodiment, the nitrogen-containing heterocyclic compound can be a carbodiimide, such as a compound of formula (VII):
[0116]
[0117] wherein Z is as defined above. Preferably, ZN together is a nitrogen-containing heteroaryl group having 5 to 6 atoms in the aromatic ring, of which 1 to 3 atoms are heteroatoms selected from O, N and S, of which at least 1 is N. Carbodiimide (VII) is more preferably 1,1'-carbonyl-diimidazole and the like.
[0118] At least 2 molar equivalents of carbodiimide should be used per mole of dicarboxylic acid diamide (VI). Theoretically, the reaction will produce 2 molar equivalents of carbon dioxide and 2 molar equivalents of imidazole per mole of dicarboxylic acid diamide (VI). The emission of carbon dioxide gas indicates that the reaction is ongoing. The reaction can be carried out under reduced pressure.
[0119] In another embodiment, the nitrogen-containing heterocyclic compound can be an N-hydroxy heterocyclic compound of formula (VIII):
[0120]
[0121] wherein ZN together is a nitrogen-containing heterocyclic group having 5 to 6 atoms in the heterocyclic ring, wherein 1 is N, and Z is an α,ω-organic diketone diyl group. For example, an α,ω-organic diketone diyl group can be represented as –C(O)R 4 C(O)-, where R 4 It is an alkanediyl group or an alkenediyl group having 2 or 3 carbon atoms. The N-hydroxyheterocyclic compound (VIII) is most preferably N-hydroxysuccinimide.
[0122] The second reaction step can be carried out by dissolving the dicarboxylic acid diamide (VI) in a solvent such as anhydrous dimethylformamide and then adding the nitrogen-containing heterocyclic compound (VII) or (VIII). The activated dicarboxylic acid derivative (I) is precipitated from the solution. The product is collected by filtration, washed with anhydrous ethyl acetate, and dried under reduced pressure.
[0123] Returning to the first step of the method of the present invention, the source collagen comprising one or both of lysine and hydroxylysine residues can be reacted with an activated dicarboxylic acid derivative comprising a disulfide group, such as an activated dicarboxylic acid derivative of formula (I) to provide a collagen comprising an SS bond, such as one or more collagens comprising type I, type II, type III, type IV, type V, type VI, type IX, type X, and type XI of an SS bond. In this reaction, the carbonyl group of the activated dicarboxylic acid derivative can react with the ε-amino group of the lysine or hydroxylysine residue present in the collagen to form an amide bond, thereby incorporating a disulfide group. The reaction can be represented as:
[0124] ZN-C(O)-R 3 -C(O)-NH-R 1 -SSR 2 -NH-C(O)-R3 -C(O)-NZ(I)+Collagen-NH 2 →
[0125] ZN-C(O)-R 3 -C(O)-NH-R 1 -SSR 2 -NH-C(O)-R 3 -C(O)-NH-Collagen+HNZ
[0126] When the two activated carboxyl groups of the activated dicarboxylic acid derivative react with collagen, especially with different collagen triple helices or fibrils, the reaction can proceed to provide cross-linked collagen:
[0127] ZN-C(O)-R 3 -C(O)-NH-R 1 -SSR 2 -NH-C(O)-R 3 -C(O)-NH-collagen+collagen-NH 2 →
[0128] Collagen-HN-C(O)-R 3 -C(O)-NH-R 1 -SSR 2 -NH-C(O)-R 3 -C(O)-NH-Collagen+HNZ
[0129] The reaction can be carried out by dissolving the source collagen in a solvent. The dissolution of the source collagen can be carried out in two steps. In the first step, the source collagen can be mixed with methanol. In the second step, a polar aprotic solvent is added. For example, the source collagen can be added to a mixture of methanol and dimethyl sulfoxide and allowed to swell. Additional dimethyl sulfoxide can be added under stirring until the source collagen is completely dissolved. Methanol can then be removed from the solution by evaporation under reduced pressure. This dissolution process can be used with de-atelopeptide collagen and telopeptide collagen.
[0130] The activated dicarboxylic acid derivative can then be dissolved in a solvent, particularly an anhydrous polar aprotic solvent such as dimethyl sulfoxide. Since the activated dicarboxylic acid derivative of formula (I) is sensitive to water, the reaction with collagen is preferably carried out in an anhydrous polar aprotic solvent such as dimethyl sulfoxide. The activated dicarboxylic acid derivative dissolved in the solvent is then added to the source collagen solution. The carbonyl group of the activated dicarboxylic acid derivative can react with the ε-amino group of the lysine or hydroxylysine residue present in the source collagen to form an amide bond.
[0131] The mixture can be stirred at room temperature, for example 22 ° C, until a gel is formed. The mixture containing the gel can then be kept undisturbed, for example for 12 to 18 hours. Dimethyl sulfoxide can then be extracted from the gel by mixing with excess acetone, the collagen gel is collected by decantation, and then remixed with more acetone. The mixture can then be stirred, for example for 0.5 to 1 hour, followed by separation of the collagen by filtration, washing with acetone, then washing with water-ethanol (30:70 v / v) and dehydrating with ethanol. Thus providing a jellyfish collagen comprising SS bonds.
[0132] In an alternative embodiment, jellyfish collagen comprising SS bonds can be provided by modifying a collagen binding protein to include a photoreactive crosslinker comprising a disulfide group, combining it with the jellyfish collagen to provide a complex and irradiating the complex to crosslink the photoreactive crosslinker to incorporate disulfide groups into the collagen.
[0133] This approach allows the generation of thiol groups in collagen by creating protein binding sites on jellyfish collagen using a site-specific photocrosslinking strategy. This involves the introduction of cysteine residues into collagen binding proteins by site-directed mutagenesis. Photoreactive crosslinkers, preferably APDP, can be introduced into cysteine-SH groups on proteins. The complex of APDP-modified protein and collagen can be crosslinked by ultraviolet (uv) irradiation. Disulfide bonds can then be crosslinked by reduction cleavage and -SH groups can be generated on jellyfish collagen.
[0134] In the first step, a collagen binding protein including a cysteine residue is provided. The cysteine residue is essential because the cysteine residue includes a sulfhydryl group necessary for reacting with a cross-linking agent. The collagen binding protein can be, for example, a pigment epithelium derived factor (PEDF). PEDF is a known anti-angiogenic / neurotrophic factor with a collagen binding site identified as disclosed in Yasui et al. Biochemistry, 2003, 42, pp. 3160-3167.
[0135] If necessary, if cysteine is not present or if the collagen binding protein does not contain enough cysteine, cysteine can be incorporated into the collagen binding protein. Cysteine substitution can be performed by site-directed mutagenesis, for example, where the collagen binding site is located at (F383) and the opposite surface of the site (Y211). Methods for performing such site-directed mutagenesis are found in Journal of Biological Chemistry (JDJ Biol. Chem.) 2002, 277, 4223-4231 and Redox Biochemistry (RR Biochemistry) 1992, 31, 9526-9532.
[0136] The sulfhydryl groups introduced as a result of the cysteine substitution can then react with a photoreactive crosslinker. The photoreactive crosslinker should be difunctional. Specifically, the photoreactive crosslinker should include a functional group that is capable of reacting with the sulfhydryl groups to produce a disulfide bond. One such suitable functional group is a pyridyl-disulfide group, i.e., C 5 NH 5 -SS-, especially 2-pyridyldisulfide. The photoreactive crosslinking agent should also include a functional group that can crosslink with collagen under light irradiation. One such suitable functional group is an azide group, especially an aryl azide group, such as phenyl azide, especially p-C 6 H 4 -N 3 .
[0137] N-[4-(p-azidosalicylamido)butyl]-3'-(2'pyridyldithio)propionamide (APDP) is an example of a preferred photoreactive crosslinker. The disulfide group of APDP can react with the sulfhydryl group of cysteine to generate a disulfide bond between cysteine and the photoreactive crosslinker, thereby providing a photoreactive crosslinker-modified collagen binding protein including an SS group. As part of this reaction, 2-pyridinethione is released as a leaving group.
[0138] The collagen binding protein modified by the photoreactive crosslinker can then be combined with the jellyfish collagen to provide a complex of the collagen binding protein modified by the photoreactive crosslinker and the jellyfish collagen. In this step, the collagen binding protein modified by the photoreactive crosslinker binds to the protein binding site of the jellyfish collagen to form a complex. The complex of the collagen binding protein modified by the photoreactive crosslinker and the collagen can then be irradiated, for example, with ultraviolet (UV) light. Irradiation causes the crosslinkable functional groups present on the photoreactive crosslinker to form covalent bonds with adjacent collagens in the complex. For example, when the crosslinkable functional group is phenyl azide, irradiation within a wavelength range of 250nm to 280nm will produce nitrenes, which can then attack nucleophilic or active hydrogen groups on the collagen, such as CH or C-NH 2 , to produce crosslinks by inserting CH or NH bonds. In this way, a collagen binding protein modified with a photoreactive crosslinker including SS groups is incorporated into collagen to provide collagen including SS bonds. Obviously, disulfide groups will be provided near the collagen protein binding site through this approach.
[0139] Sulfhydryl groups can then be introduced into collagen comprising SS bonds, which can be provided by any of the methods discussed above, i.e., using an activated dicarboxylic acid derivative or a photoreactive crosslinking agent method. A jellyfish collagen comprising SS bonds can be reacted with a suitable reducing agent. The reducing agent reduces the disulfide bonds to two sulfhydryl groups, thereby cleaving the activated dicarboxylic acid derivative residue or photoreactive crosslinking agent residue where the disulfide group is located. Such reduction is carried out by two consecutive thiol-disulfide exchange reactions, resulting in the reduction of the disulfide groups to produce a jellyfish collagen comprising a sulfhydryl (-SH) group.
[0140] Suitable reducing agents include, for example, dithiothreitol (DTT), (2S)-2-amino-1,4-dimercaptobutane (DTBA), and tris(2-carboxyethyl)phosphine HCl (TCEP hydrochloride). Dithiothreitol is a preferred reducing agent.
[0141] The reduction step can be performed by adding the jellyfish collagen comprising SS bonds to a buffer solution, such as a glycine / sodium hydroxide buffer solution having a pH in the range of 7.5 to 9.5, more preferably about 8 to 9.5, preferably about 8.0. The jellyfish collagen comprising SS bonds may be acidic in nature, and if so, may need to be neutralized with a base such as sodium hydroxide.
[0142] Preferably, at least two molar equivalents of DTT reducing agent can be added per mole of disulfide groups in the same buffer, and the reaction is carried out at 30° C. for 2 to 6 hours. After the reaction is completed, the pH of the liquid can be reduced to 2, for example using HCl. The mixture can then be dialyzed with a dilute HCl solution, centrifuged, and freeze-dried to provide a jellyfish collagen thiol with a -SH group.
[0143] Reduction may result in slight degradation of the collagen chains. Therefore, shorter reaction times, lower pH, and lower temperatures can be used to minimize any degradation.
[0144] Obviously, when the collagen binding protein modified by the photoreactive crosslinker is used to provide the jellyfish collagen including the SS bond, before the step of forming the collagen thiol, the modified collagen binding protein will still be connected to the collagen by the photoreactive crosslinker step d. The reduction of the SS bond will cleave the SS bond of the photoreactive crosslinker.
[0145] When the jellyfish collagen comprises one or both of lysine and hydroxylysine residues, a jellyfish collagen thiol comprising a lysine or hydroxylysine residue of formula (X) is provided:
[0146]
[0147] Where R 1 , R3 and R 5 is as defined above. For example, R 1 and R 3 is independently selected from a divalent linking group, preferably a divalent organic linking group, more preferably a divalent hydrocarbon linking group, such as an alkanediyl group having 1 to 6 carbon atoms or an alkenediyl group or an alkynediyl group having 2 to 6 carbon atoms. Still more preferably, R 1 and R 3 independently represents ethylenediyl or propylenediyl, most preferably ethylenediyl (i.e. -CH 2 CH 2 -). When the amino acid residue is a lysine residue, R 5 is H. When the amino acid residue is a hydroxylysine residue, R 5 is OH; X is selected from the group OH and a chemical bond, and Y is selected from H and a chemical bond, provided that one or both of X and Y are chemical bonds that form peptide bonds within collagen. The peptide chain that forms part of the modified collagen is enclosed in "[]" in formula (X). The residue may be in a terminal position of the peptide, for example if one or the other of X and Y is OH and H, respectively. If both X and Y are peptide bonds, the lysine residue is non-terminal in the peptide chain, forming part of collagen.
[0148] The present invention further provides a method for making the jellyfish collagen disclosed herein, which may be thiolated or not thiolated, the method further comprising the steps of: i) mixing a solution of purified jellyfish collagen or collagen thiol with an aqueous neutralizing buffer; and ii) incubating the mixture for a sufficient amount of time to allow collagen fibrils to form, wherein a cross-linking agent is added in step i) or ii) to provide cross-linked collagen.
[0149] The term 'neutralizing buffer' refers to any buffer that can dilute the purified jellyfish collagen solution to increase or decrease the pH to pH 4 to pH 9. The composition of the neutralizing buffer is not particularly limited, as long as it must increase or decrease the pH of the purified jellyfish collagen solution so that the formation of collagen fibrils can proceed. In addition, the buffer must be substantially free of ions, compounds or molecules that may interfere with any cross-linking process. Therefore, a buffer substantially free of unreacted amines is particularly desirable. As a non-limiting example only, the neutralizing buffer can be 1x to 10x phosphate buffered saline (PBS), where 1x or 10x refers to the concentration of PBS. The composition of 1x PBS is well known to technicians. The exact concentration of PBS (i.e., 1x or, for example, 10x) will depend entirely on the dilution factor required when mixing with the purified jellyfish collagen solution so that the purified jellyfish collagen solution is substantially neutralized, so that the formation of collagen fibrils can proceed. In some embodiments, the neutralizing buffer is sodium hydroxide.
[0150] The term 'fibrillogenesis' or 'fibrillogenesis' refers to the process by which collagen molecules undergo controlled aggregation to form higher order, well-structured macromolecular assemblies. In vivo collagen is primarily an extracellular protein that aggregates into fibrillar structures to provide structural support to components of the surrounding tissue and / or extracellular matrix. Aggregation of collagen, particularly mammalian collagen, is a well-known phenomenon. Different isoforms of mammalian and marine collagen preferentially aggregate into different macromolecular structures. The unique macromolecular structures formed by each collagen isoform are controlled by the physicochemical properties of the collagen polypeptides and the conditions that promote fibrillogenesis. Higher order collagen structures, i.e., collagen fibrils obtained from mammals or fish, have been utilized in vitro to produce mammalian and / or fish collagen hydrogels. Therefore, in order to form hydrogels from jellyfish collagen, jellyfish collagen is preferably assembled into higher order structures. Preferably, the higher order structures are fibrils.
[0151] It is contemplated that any cross-linking agent known to cross-link under conditions that form collagen fibrils will be a suitable cross-linking agent for use in the present invention. In certain applications, it may be desirable to use a cross-linking agent that is non-toxic to cells. In certain embodiments, the cross-linking agent may be selected from genipin, 1,4-BDDGE, or dichloroal-acrylic acid. Preferably, the cross-linking agent is genipin or 1,4-BDDGE.
[0152] The invention will now be further described with reference to the following examples and studies.
[0153] Examples
[0154] Example 1 - Studies to determine the effects of jellyfish collagen sponge, cross-linked jellyfish collagen sponge, and chemically modified (thiolated) jellyfish collagen paste in a mouse model of skin wound healing.
[0155] Target
[0156] Comparison of jellyfish collagen sponge; cross-linked jellyfish collagen sponge; chemically modified (thiolated) jellyfish collagen paste with commercially available wound products Performance in an excisional skin wound healing model in C57BL / 6J mice.
[0157] program
[0158] Eighty (80) male C57BL / 6J mice, aged 5 to 6 weeks, were provided by Epistem and divided into two cohorts of 40 mice each. The mice in each cohort were acclimated for two weeks and eight mice per cohort were randomly assigned to one of five treatment groups. On day 0 (injury day), all animals were anesthetized, shaved, and two 6 mm diameter excisional wounds were made at the same relative locations on either side of the dorsal midline of each mouse. Depending on the designated treatment group, one of the following dressings was applied to the wound cavity of each mouse: preformed jellyfish collagen sponge, standard or cross-linked; chemically modified (thiolated) collagen gel; pre-cut Dressings; No treatment. Following wound treatment, a Tegaderm film dressing was applied to cover each wound. Mice were placed in an incubator after the procedure and allowed to recover from anesthesia before being returned to their housing unit. All mice were housed individually from the time of wounding. Wounds were monitored at least daily for any signs of infection and shedding of the Tegaderm film dressing. Visual assessment of wound condition and measurement of wound width could not be accurately performed over the life of the study due to Tegaderm folding caused by normal mouse activity.
[0159] From each cohort, four mice in each treatment group were euthanized 3 days after injury, and four mice were euthanized 7 days after injury. Mice were killed humanely by cervical dislocation, and dorsal skin strips containing two wounds were excised. Wound width was determined using a digital caliper; the wound was also scored subjectively visually (1 to 5) according to the degree of healing visible to the naked eye. A single wound was divided into two, half was quick-frozen in liquid nitrogen, and half was fixed in 10% neutral buffered formalin for histological processing and preparation of transverse wound sections stained with hematoxylin (Haematoxylin) and eosin (Eosin, H & E). For each wound section, computer-assisted morphometry (Zeiss Axiohome system) was used to determine wound width and epithelial regeneration. In addition, a subjective score of granulation tissue maturity was assigned to each wound, and the area of granulation tissue was determined.
[0160] result
[0161] From day 3 to day 7, each treatment group showed healing of the excisional wound, as evidenced by a decrease in wound width ( Figure 1 and 2 ), the percentage of epithelial regeneration increased ( Figure 3 ) and increased granulation ( Figure 4 )(Granulation tissue maturity and granulation area). For the Tegaderm-only control group, the mean wound width decreased from (4.57±0.93) mm on day 3 to (3.71±0.92) mm on day 7 (numbers quoted are mean±standard deviation).
[0162] The cross-linked jellyfish collagen sponge group showed the greatest amount of wound closure, with an average wound width of (5.11±1.46) mm on day 3 and (3.16±0.80) mm on day 7. Figure 2 ).exist The least wound closure was observed in the group with an average wound width of (3.96±1.03) mm on day 7.
[0163] Epithelial regeneration in the Tegaderm group alone progressed from (17.2±10.5)% on day 3 to (59.7±37.9)% on day 7. The group showed the most epithelial regeneration at day 7, which was (73.2±27.1)%, and the cross-linked jellyfish collagen sponge group showed a similar level of epithelial regeneration, which was (70.7±30.3)% ( Figure 3 ).
[0164] Granulation scores and granulation areas (percentage of total wound area) increased from day 3 to day 7 in all groups ( Figure 4For the Tegaderm-only group, the mean granulation score on day 3 was (1.46 ± 0.52), with granulation tissue accounting for (33 ± 24)% of the wound space. By day 7, the mean granulation score for this group had increased to (2.08 ± 0.51), with (61 ± 31)% of the wound space being granulation tissue. The group with cross-linked jellyfish collagen sponge had the lowest granulation score at day 3, (1.17 ± 0.39), with only (5 ± 6)% of the wound space being granulation tissue; however, by day 7, this group had the highest granulation tissue score, (2.63 ± 0.52), with (81 ± 20)% of the wound space being granulation tissue. The jellyfish collagen sponge group and the chemically modified (thiolated) collagen paste group showed similar amounts of granulation tissue as the Tegaderm alone group at day 3, whereas wound spaces treated with cross-linked jellyfish collagen sponge had approximately half the amount of granulation tissue at day 3, at only (15 ± 21)%. For the chemically modified (thiolated) collagen paste group, the lowest mean granulation tissue score (1.67 ± 0.50) was observed at day 7, with only (48 ± 41)% of the wound space being granulation tissue. Despite differences in the proportion of wound space with granulation on day 3, both types of jellyfish collagen sponges had similar levels of granulation on day 7, with scores of (2.30 ± 0.82) and (2.18 ± 0.75) for standard and cross-linked sponges, respectively.
[0165] Observation of H&E-stained wound cross sections showed that on day 3 The clear structure of the cross-linked jellyfish collagen sponge covers the wound. With the cross-linked jellyfish collagen sponge, the migration of the healing epithelium beneath the sponge is evident. Representative images of each group of wounds are shown in Figure 2. Figure 5 (Tegaderm only), Figure 6 (Jellyfish collagen sponge), Figure 7 (Chemically modified (thiolated) jellyfish collagen paste), Figure 8 (cross-linked jellyfish collagen sponge) and Fig. 9 These show the wound edges, with uninjured skin (usually with a hyperplastic epithelial layer) adjacent to the wound. In the images, the Tegaderm dressing can be seen as a wavy line above the skin surface.
[0166] Collagen I immunoreactivity was observed in all wound sections; representative images are shown in Fig.10 , which is from a wound that also appears in the H&E image. Prominent collagen 1 immunoreactivity can be observed at the wound edge and across the wound space at day 7.
[0167] in conclusion
[0168] The animals tolerated the different test items well, with no adverse reactions. Seven days after injury, the majority of animals had good wound healing with signs of re-epithelialization, and both the amount and maturity of granulation tissue increased over time. Both types of jellyfish collagen sponges outperformed the Tegaderm dressing alone, with the cross-linked jellyfish collagen sponge also showing more re-epithelialization in terms of the extent of tissue granulation in the wound space at day 7. In contrast, the jellyfish sponges and the reference product The dressings performed similarly.
[0169] This study shows that jellyfish collagen is a suitable alternative that is at least as effective as known products on the market for treating wounds. These known products are usually of mammalian origin and therefore have many disadvantages. Therefore, it would be extremely advantageous to provide an alternative source of collagen suitable for treating wounds.
[0170] Example 2 - Immunohistochemical labeling of mouse wound healing formalin-fixed paraffin-embedded (FFPE) samples using anti-mouse CD31 antibody.
[0171] Target
[0172] The goal of this study was to section 152 FFPE mouse wounds obtained from study 18 / 099, which was designed to determine the effect of the test item in a murine model of cutaneous wound healing, and perform immunohistochemical labeling with anti-mouse CD31. CD31 is an endothelial cell marker that is commonly used to identify and measure angiogenesis.
[0173] program
[0174] 152 FFPE mouse wounds obtained during Study 18 / 099 (a study to determine the effect of the test item in a murine model of skin wound healing at day 3 and day 7 time points) were sectioned at 3 μm thickness to provide one slide with two non-consecutive sections per slide. The sections were mounted on charged slides and dried overnight at 37°C.
[0175] 152 FFPE sections were dewaxed and rehydrated before antigen retrieval using proteinase K (Dako S3020) proteolytic digestion for 5 minutes at room temperature. Endogenous peroxidase was blocked with 0.3% H2O2 in TBST for 15 minutes, followed by nonspecific binding with 2.5% goat serum for 30 minutes. The sections were incubated with anti-mouse CD31, rat monoclonal antibody, clone MEC13.3 (BD Pharmingen 550274) at room temperature for 1 hour at 0.3125 μg / ml. The corresponding rat monoclonal IgG2a isotype control was included in one sample at a concentration matched to the primary antibody. Untreated mouse skin samples were included as positive tissue controls. The sections were washed in TBST, and then the sections were incubated with anti-rat, mouse adsorbed polymers (Vector ImmPress MP-7444). All markers were visualized using DAB (Vector ImmPact SK-4105), and the sections were counterstained with hematoxylin before permanent mounting. Each labeled slide was checked against its corresponding block to confirm the match and was examined microscopically as part of the quality control procedure.
[0176] Thirty representative images were captured using the AxioVision imaging system, which consists of a Zeiss Axioscope A1 microscope, an AxioCam MRc camera, and AxioVision software mounted on a computer workstation to capture images. Images were captured using a x10 objective.
[0177] On Day 3 ( Fig.11 , Fig.13 , Fig.15 , Fig.17 and Fig.19 ) and Day 7 ( Fig.12 , Fig.14 , Fig.16 , Fig.18 and Fig. 20 ) Representative images from each treated wound dressing group (Tegaderm only, jellyfish collagen sponge, chemically modified (thiolated) jellyfish collagen paste, cross-linked jellyfish collagen sponge, and Puracol) were taken. For orientation, each wound was imaged with the uppermost layer of the epidermis, i.e., at the top of the image.
[0178] Results and Conclusions
[0179] Wound samples collected from Study 18 / 099 were successfully labeled for the mouse-specific endothelial cell marker CD31, indicating that angiogenesis occurred in these jellyfish collagen-treated samples.
[0180] As with the in vivo data, the in vitro data described above suggest that jellyfish collagen is a suitable alternative to bovine collagen for wound treatment that lacks the disadvantages associated with the use of mammalian collagen, such as increased risk of disease / prion transmission, increased risk of contamination, and the high costs associated with obtaining collagen from mammalian sources. This finding is surprising given the distinct physicochemical and amino acid properties of jellyfish collagen and mammalian collagen.
[0181] Example 3 - Study on the effect of jellyfish-derived collagen formulation on db / db (BKS.CG-m Dock 7 m + / _+Lepr db / J) Effects of full-thickness excisional wound healing in diabetic mice.
[0182] Target
[0183] The effects of three jellyfish-derived collagen formulations on wound healing in BKS.Cg-m Dock7m+ / +Leprdb / J (db / db) diabetic mice, a model of delayed skin wound healing, were investigated.
[0184] program
[0185] Tested materials:
[0186] - 96-well plate-formed (approximately 6 mm in diameter) Jellagen non-crosslinked sponge - sterilized with CHCl3.
[0187] - Micronized 0.5% EDC* Cross-linked Jellagen powder - CHCl3 sterile (4 g).
[0188] - Micronized 1% EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride) cross-linked Jellagen powder - CHCl3 sterile (4 g).
[0189] -Promogran TM (Protease Regulated Matrix, Acelity, USA). Batch No. 1912V001; Expiration Date February 28, 2021.
[0190] BKS.Cg-mDock7m+ / +Leprdb / J diabetic mouse model
[0191] The following is a brief overview of the methods used. The survival phase of this study was conducted between September 19, 2019 and October 9, 2019.
[0192] Diabetic mice (BKS.Cg-m Dock7m+ / +Leprdb / J, Jackson Labs, Bar Harbour, ME, USA) approximately 9 to 10 weeks old were brought to the UK and acclimatized for one week before the start of the study. Animals were maintained according to UK Home Office regulations and specific requirements for diabetic animals. Animals were randomly assigned to 5 treatment groups (Table 1).
[0193] Table 1 - Experimental groups
[0194]
[0195] In brief, mice were anesthetized with isoflurane and air, and their dorsal skin was clamped and cleaned according to the protocol. A single standardized full-thickness wound (10mm x 10mm) was created on the left dorsal side about 5mm from the spine. The wound was cleaned with a gauze swab soaked with sterile saline and dried with sterile gauze. Then 15 μL of sterile saline was applied to the surface of each wound. Then the material to be tested was directly applied to the wound surface moistened with saline.
[0196] Wounds in Group 2 received a non-cross-linked Jellagen sponge approximately 6 mm in diameter (96 pores); those in Group 5 received a 6 mm commercial comparator Promogran sponge. TM (Acelity, USA) discs, and Groups 3 and 4 received 5 mg EDC-crosslinked Jellagen powder (0.5% and 1.0% EDC crosslinked, respectively). After product application, the semi-occlusive film dressing Tegaderm TM All wounds were coated with a film (3M Deutschland GmbH, Germany). The film dressing was checked daily throughout the study and replaced if it fell off.
[0197] On days 4, 8, 12, and 16 after wounding, all animals were re-anesthetized, their film dressings and any loose debris removed, and their wounds (and marginal skin) were gently cleaned using sterile saline soaked gauze (without disturbing any existing product in the wound). The wounds were then photographed (not shown), moistened with 15 μl of sterile saline, and the product was reapplied to the wounds of selected groups on selected days.
[0198] Initially, it was intended that Group 2 (non-cross-linked Jellagen sponge) and Group 5 (Promogran TM, Acelity, USA) applied the products a second time on day 4 post-injury. As no significant degradation of any of these products was observed, it was decided (and agreed with the Sponsor) that no re-applications would be made at this time. However, re-applications of the products were made on days 8, 12 and 16 post-injury (without prior removal of the existing non-degraded product).
[0199] After reapplying product (where indicated), use Tegaderm TM The wounds were re-dressed with film dressings (as above) and the animals were allowed to recover in a warm environment (approximately 35° C.) Immediately after wounding and subsequently on days 4, 8, 12, 16 and 20 after cleaning, all wounds were digitally photographed along with the calibration / identification plate.
[0200] All animals were eliminated on day 20 after injury. One hour before termination, all animals received an ip injection of 5-bromo-2'-deoxyuridine (Sigma B5002) in saline (30 μg / g) to facilitate the possibility of detecting cell proliferation in tissue sections. Wound and surrounding marginal tissues were then collected from all wounds. Tissues were fixed (neutral buffered formalin, Sigma) and embedded in paraffin to facilitate histological studies.
[0201] Overview
[0202] This study examined the effects of topical application of three jellyfish-derived formulations (non-cross-linked Jellagen sponge, 0.5% EDC cross-linked Jellagen powder, and 1.0% EDC cross-linked Jellagen powder) on the repair of full-thickness excisional skin wounds in healing-impaired db / db diabetic mice.
[0203] The healing of wounds receiving these formulations / products was compared with that of wounds receiving a commercial comparator (Promogran TM The healing of wounds treated with protease-regulated matrix (Acelity, USA) was compared with that of wounds treated with control (film dressing only).
[0204] Wound healing was assessed over a 20-day period based on (i) the onset of a new dermal repair response and (ii) wound closure. The onset of new dermal tissue formation was expressed as the number of wounds per group that responded at each time point. Wound closure was considered from an overall perspective and in terms of its components, wound contraction and wound epithelial regeneration. Wound closure (contraction and epithelial regeneration) was determined by digital photographs taken at days 0, 4, 8, 12, 16, and 20 after injury. At the histological level, H&E stained sections of wound tissue (collected on day 20) were briefly considered and compared in terms of granulation tissue formation and epithelial regeneration, and in terms of its potential use as a structural scaffold to support tissue regeneration (for both EDC-crosslinked powder formulations).
[0205] Summary of Results - Wound Closure
[0206] Each wound and identification / calibration plate were digitally photographed immediately after wounding and subsequently at Days 4, 8, 12, 16, and 20. For a given wound at a given time point, wound closure was expressed as the remaining percent wound area relative to the initial wound area immediately after wounding (i.e., Day 0). The mean remaining percent wound area data for all treatment groups are described in Table 2 below and are presented in Table 2. Fig.21 Shown in.
[0207] Table 2 - Percent "Remaining Wound Area" data for all study groups.
[0208]
[0209] When considering wound closure (in terms of '% open wound area' over time), the following was observed:
[0210] - From day 12 onwards, all three Jellagen products evaluated were found to significantly promote closure compared to the 'film dressing only' control treatment.
[0211] - When comparing the three Jellagen products, application of the uncrosslinked sponge produced similar levels of occlusion as the 1.0% EDC crosslinked powder, with both found to be slightly higher than the response to the 1.0% EDC crosslinked powder.No statistically significant differences in occlusion were observed between the three Jellagen product treatment groups.
[0212] Results Summary - Wound Contraction
[0213] Contraction is the centripetal movement of the wound edges due to compaction of granulation tissue within the wound "body". The "compacting" forces driving this process are thought to exist in cells of the fibroblast lineage. In this study, percent contraction was calculated as follows:
[0214]
[0215] Wounds in non-diabetic mice close primarily by contraction, whereas wounds in diabetic mice (such as those used in this study) have a significantly reduced ability to contract (possibly due to insufficient granulation tissue formation). Thus, untreated wounds in diabetic animals tend to close by epithelial regeneration to a greater extent than epithelial regeneration in non-diabetic animals. The observation of enhanced contraction suggests improved granulation tissue function, which in turn could be explained by an increase in the amount of granulation tissue formed, an increase in the rate of formation, or an increase in the contractile capacity of the tissue. The mean percentage wound contraction data for all treatment groups are depicted in Table 3 (below) and are presented in Table 3. Fig. 22 Shown in.
[0216] Table 3 - Summary of "Percent Wound Contraction" data.
[0217]
[0218] When considering the effect of treatment on wound contraction, the following was observed:
[0219] - From day 8 onwards, all considered treatments were found to significantly accelerate wound contraction compared to the 'film dressing only' control treatment.
[0220] - When comparing the three Jellagen products, contractions in response to the 1.0% EDC cross-linked powder tended to be more extensive than those observed in response to 0.5%, which in turn tended to be more extensive than contractions in response to the non-cross-linked sponge. Statistical analysis found that the use of the 1.0% EDC cross-linked powder significantly enhanced contractions compared with treatment with the non-cross-linked sponge.
[0221] Results Summary - Wound Epithelial Regeneration
[0222] For a given wound, at a given time point, the area of epithelial regeneration was expressed as a percentage of the original area of the wound immediately after wounding. The average percentage wound epithelial regeneration data for all treatment groups are described in Table 4 (below) and are presented in Table 4. Fig.23 Shown in.
[0223] Table 4 - Summary of data on "Percent wound epithelial regeneration"
[0224]
[0225] When considering the effects of treatment on wound epithelial regeneration, the following were observed:
[0226] - When considering the Jellagen treated groups, application of non-crosslinked sponge was found to be more effective than application of EDC crosslinked powder.
[0227] - On days 8, 12, and 16, epithelial regeneration was found to be greater in response to the non-cross-linked sponge than in the Promogran TM observed in the treatment group; and less on day 20.
[0228] - In most studies, re-epithelialization in response to EDC cross-linked powder tended to be lower than that in response to the 'film dressing only' control treatment, although similar levels of re-epithelialization were achieved by the conclusion of the study at day 20.
[0229] Results Summary - Initiation of New Dermal Tissue Generation
[0230] All wounds in the study were visually assessed daily until day 8, and their "healing" status was subsequently determined on days 10, 12, 14, 16 and 20. Each wound was scored based on whether it showed "neodermal tissue generation activity" in the central wound area. Scoring was performed independently by two independent observers, and the average % of wounds showing "neodermal tissue generation activity" was compared between treatment groups at each assessment point. Table 5 shows the number of wounds that responded per day in each treatment group. Table 6 shows the average response time for each group. It should be noted that since 10 of the 10 wounds in the 'film dressing only' treatment group did not respond during the study, the average 'response time' for this group is an unknown value greater than 20.
[0231] Table 5 - Number of wounds showing 'start of new dermal tissue formation' ( Underline Indicates that 100% of the start has been achieved)
[0232]
[0233] Table 6 - Response time (in days)
[0234]
[0235] Application of all three Jellagen products promoted the onset of 'neodermal tissue formation' within the central wound area compared to the 'film dressing only' control treatment. Of the three Jellagen treatments studied, the 1.0% EDC cross-linked powder resulted in the fastest 'onset', followed by the 0.5% EDC cross-linked powder and finally the non-cross-linked sponge. All three products were significantly different from the Promogran TM Just as effective (if not more effective).
[0236] Summary of Results - Wound Histology
[0237] At the conclusion of the study on day 20 after injury, wound tissue and the surrounding skin of each wound were collected from each animal. Tissue samples were fixed, processed and embedded in paraffin. Sections (approximately 6 μm) were taken from the center of each wound in the cranial and caudal direction. These sections were stained with hematoxylin and eosin (H&E) and digitally scanned. Fig.24 and Fig.25 Representative examples of wound appearance in each experimental group are shown. Typical levels of granulation tissue deposition and extent of wound epithelial regeneration for each group of wounds are described below.
[0238] Control treated wounds showed limited granulation tissue formation and limited re-epithelialization (both confined to the wound edges).
[0239] Application of the non-crosslinked sponge resulted in increased granulation tissue formation and epithelial regeneration relative to the control. Granulation tissue formed throughout the wound base, although the 'quality' was found to be variable. No product residue was evident in the majority of wounds.
[0240] Application of two EDC cross-linked powders resulted in increased granulation tissue formation with minimal re-epithelialization in most wounds. These products appear to act as a scaffold for granulation tissue deposition and (when fully cellularized) may support re-epithelialization. Based on gross wound images and histological appearance, these products did not appear to degrade significantly over the 20-day study period.
[0241] EDC cross-linked jellyfish collagen powder appears to promote the growth of new blood vessels from the wound edge into it. This is most evident with the 1.0% powder (visible to the naked eye as a gradual reddening of the outer edge of the wound surface hydration mass) and is also evident on tissue sections ( Fig.26 ).
[0242] Study Results
[0243] All three Jellagen products evaluated in this study were found to have a positive impact on wound healing in the db / db diabetic mouse impaired healing model.
[0244] Non-cross-linked collagen sponges promoted wound closure by promoting contraction and re-epithelialization and were found to promote granulation tissue formation. The sponge material underwent extensive compaction, limited degradation, and did not appear to integrate into the wound tissue.
[0245] The cross-linked powders promoted wound closure primarily by promoting the wound contraction process, which can be explained by the ability of these products to serve as scaffolds for granulation tissue formation.
[0246] Example 4 - Study on the effect of jellyfish-derived collagen formulation on db / db (BKS.Cg-m Dock7 m + / +Leprdb / J) Effects of full-thickness excisional wound healing in diabetic mice
[0247] Target
[0248] The effects of three jellyfish-derived collagen formulations on wound healing in BKS.Cg-m Dock7m+ / +Leprdb / J (db / db) diabetic mice, a model of delayed skin wound healing, were investigated.
[0249] program
[0250] Tested materials:
[0251] - Cross-linked jellyfish collagen sponge (Jellagen). Prepared in 24-well plates using 500 μL AMY2 (4.5 mg / mL). 1% EDC cross-linked CHCl 3 Sterile. DOM October 2020. Sponge cut to wound size.
[0252] -Micronized 1% EDC* cross-linked jellyfish collagen powder (Jellagen) - CHCl 3 Sterile (approximately 2.5 mg in individual wound aliquots).
[0253] -Micronized Thiolated Jellyfish Collagen Powder (Jellagen) - CHCl 3 Sterile (approximately 2.5 mg in individual wound aliquots).
[0254] -Comparables: Flowable wound matrix (Integra Lifesciences Inc. Princeton, USA). Product code: FDR 301, batch number: 4679547, expiration date September 30, 2021.
[0255] BKS.Cg-m Dock7m+ / + Leprdb / J diabetic mouse model
[0256] The following is a brief overview of the methodology employed.
[0257] Diabetic mice (BKS.Cg-m Dock7m+ / +Leprdb / J, Jackson Laboratory, Bar Harbor, ME, USA) approximately 9 to 10 weeks old were brought to the UK and acclimatized for one week before the start of the study. Animals were maintained in accordance with UK Home Office regulations and specific requirements for diabetic animals. Animals were randomly assigned to five treatment groups (Table 7).
[0258] Table 7 - Experimental groups
[0259]
[0260] In brief, mice were anesthetized with isoflurane and air, and their dorsal skin was clamped and cleaned according to the protocol. A single standardized full-thickness wound (10mm x 10mm) was created on the left dorsal side about 5mm from the spine. The wound was cleaned with a gauze swab soaked with sterile saline and dried with sterile gauze. Then 15 μL of sterile saline was applied to the surface of each wound. Then the material to be tested was directly applied to the wound surface moistened with saline.
[0261] On the days of reapplication (see Table 7 above), animals were re-anesthetized, their film dressings and any loose debris removed, and their wounds (and marginal skin) were gently cleaned using sterile saline soaked gauze (without disturbing any existing product within the wound). The wounds were then photographed (not shown), moistened with 15 μl sterile saline, and the product was reapplied to the wounds of the selected groups on the selected days. After reapplication of the product (where indicated), the wounds were treated with Tegaderm TM The wound was re-applied with a film dressing and the animals were allowed to recover in a warm environment (approximately 35° C.) The wounds were digitally photographed along with the calibration / identification plate immediately after injury and on days 4, 8, 12, 16, 20, 24, 28, 35, 42, 49, 56, and 63 after injury.
[0262] Eight animals from each group were sacrificed on day 35 after injury. All remaining animals were killed on day 63 after injury.
[0263] Summary of Results – Wound Closure
[0264] Each wound and identification / calibration plate were digitally photographed immediately after wounding and subsequently at Days 4, 8, 12, 16, 20, 24, 28, 35, 42, 49, 56, and 63. For a given wound at a given time point, wound closure was expressed as the remaining percent wound area relative to the initial wound area immediately after wounding (i.e., Day 0). The mean remaining percent wound area data for all treatment groups are presented in Fig. 27 The wound margins of the XL sponge-treated group were not always clearly visible due to the presence of the sponge, so the values for this test group are not included. Fig. 27 middle.
[0265] When considering wound closure (in terms of '% open wound area' over time), the following was observed:
[0266] - All considered treatments were found to increase closure compared to the 'film dressing only' control treatment until at least day 35 after wounding. Between days 35 and 63, some regression in wound healing was observed in all groups except the thiolated powder and control treatment groups.
[0267] - Each Jellagen product evaluated was found to significantly improve wound closure compared to the 'film dressing only' control treatment from at least day 12 (day 4 for 1.0% EDC XL powder and thiolated powder) Fig. 27 ).
[0268] - When comparing the two Jellagen products, wounds receiving the thiolated powder showed the greatest response at day 35 (n=12), followed by 1% EDC XL powder ( Fig.28 No significant differences were found at later time points (after day 35) (where n=4).
[0269] - When the thiolated powder was compared to the Integra product, at day 35 (n=12) ( Fig.29 ) observed a very similar closed curve, and from day 42 to day 63 (n = 4) ( Fig. 27 ) A slight increase in closure was observed for the thiolated powders.
[0270] Summary of Results – Wound Contraction
[0271] Contraction is the centripetal movement of the wound edges due to compaction of granulation tissue within the wound "body". The "compacting" forces driving this process are thought to exist in cells of the fibroblast lineage. In this study, percent contraction was calculated as follows:
[0272]
[0273] Wounds in non-diabetic mice close primarily by contraction, whereas wounds in diabetic mice (such as those used in this study) have a significantly reduced ability to contract (possibly due to insufficient granulation tissue formation). Thus, untreated wounds in diabetic animals tend to close by epithelial regeneration to a greater extent than epithelial regeneration in non-diabetic animals. The observation of enhanced contraction suggests improved granulation tissue function, which in turn could be explained by an increase in the amount of granulation tissue formed, an increase in the rate of formation, or an increase in the contractile capacity of the tissue. The mean percentage wound contraction data for all treatment groups are given in Fig.30 Shown in.
[0274] When considering the effect of treatment on wound contraction, the following was observed:
[0275] - All considered treatments were found to significantly increase wound contraction compared to the 'film dressing only' control treatment up to at least 35 days post-injury.
[0276] - Each of the three Jellagen products evaluated was found to significantly promote wound contraction compared to the 'film dressing only' control treatment from at least day 12 (day 4 for XL sponge, day 8 for 1% EDC XL powder, and approaching significance at day 8 for thiolated powder) Fig.30 ).
[0277] - When comparing the three Jellagen products ( Fig.31 ), wounds receiving the thiolated powder showed the greatest contraction at day 35 (n=12), with the XL sponge and 1% EDC XL powder promoting slightly less contraction, comparable to the Integra product ( Fig.30 ).
[0278] - When comparing the thiolated powder to the Integra product ( Fig.32 ), an increase in shrinkage was observed for the thiolated powder, reaching statistical significance at days 20 and 28 to 42 (p≤0.029) and approaching significance at days 16 and 24 (p=0.060 and 0.068, respectively).
[0279] Summary of results – wound epithelial regeneration
[0280] For a given wound, at a given time point, the area of epithelial regeneration was expressed as a percentage of the original area of the wound immediately after wounding. The average percentage wound epithelial regeneration data for all treatment groups are described in Table 4 (below) and are presented in Table 4. Fig.33 As the sponges remained in place, it was not possible to accurately measure epithelial regeneration on wounds receiving XL sponges, and therefore the results of this treatment are not included in Fig.33 middle.
[0281] When considering the effects of treatment on wound epithelial regeneration, the following were observed:
[0282] - All considered treatments were found to increase wound epithelial regeneration compared to a 'film dressing only' control treatment until at least 35 days post-wounding.
[0283] - Both Jellagen 1% EDC XL powder and Jellagen thiolated powder products were found to significantly promote wound contraction compared to the 'film dressing only' control from at least day 16. Specifically, wounds receiving the thiolated powder showed significantly increased wound epithelial regeneration compared to control wounds from days 12 to 35 (p≤0.007), and wounds receiving the 1% EDC XL powder product showed significantly increased wound epithelial regeneration compared to control wounds from days 16 to 35 (p≤0.028), approaching significance on day 12 (p=0.052).
[0284] - When comparing 1% EDC XL powder and thiolated powder ( Fig.34 ), wounds receiving the thiolated powder showed the greatest re-epithelialization at day 35 (n=12), with 1% EDC XL powder promoting slightly less re-epithelialization.
[0285] - When comparing the thiolated powder to the Integra product ( Fig.34 ), the Integra product generally showed a slight increase in epithelial regeneration levels by day 35 after wounding, reaching significance (p≤0.039) at days 16, 28, and 35. However, the thiolated powder showed a significant increase in epithelial regeneration at day 8 after wounding (p=0.010).
[0286] Exemplary embodiments:
[0287] Item 1. A composition for treating wounds, comprising jellyfish collagen.
[0288] Item 2. The composition for use according to Item 1, wherein the wound is not associated with Epidermolysis Bullosa.
[0289] Item 3. The composition for use according to Item 1 or Item 2, wherein the jellyfish collagen is not in the form of a hydrolysate.
[0290] Item 4. The composition for use according to any one of the preceding items, wherein the jellyfish collagen is in its atelopeptide form.
[0291] Item 5. The composition for use according to any one of Items 1 to 3, wherein the jellyfish collagen is in the form of its telopeptide.
[0292] Item 6. The composition for use according to any one of the preceding items, wherein the jellyfish collagen is thiolated.
[0293] Item 7. The composition for use according to any one of Items 1 to 6, wherein the jellyfish is cross-linked.
[0294] 8. A composition for use according to any one of the preceding clauses, wherein the source of the jellyfish collagen is from the subphylum Scyphozoa.
[0295] Item 9. A composition for use according to Item 8, wherein the source of the jellyfish collagen is selected from the group consisting of: Rhizostomas pulmo, Rhopilema esculentum, Rhopilema nomadica, Stomolophus meleagris, Aurelius p., Cassiopea andromeda, Nemopilema nomurai, or any combination thereof.
[0296] Item 10. A composition for use according to any one of the preceding items, wherein the jellyfish collagen is in the form of a hydrogel, a paste, a powder, preferably a micronized powder, a film, a scaffold, a solution, a sponge matrix, a nanofiber electrospun matrix, or in a freeze-dried form.
[0297] Item 11. The composition for use according to any of the preceding items, wherein the composition further comprises at least one growth factor.
[0298] Item 12. A composition for use according to Item 11, wherein the at least one growth factor is platelet-rich plasma (PRP), epidermal growth factor 38 (EGF), transforming growth factor-β (TGF-B, TGF-B2, TGF-B3), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), granulocyte-monocyte colony-stimulating growth factor, platelet-derived growth factor, insulin-like growth factor 1 (IGF1), basic fibroblast growth factor (bFGF) and / or vascular endothelial growth factor (VEGF) or any combination thereof.
[0299] Item 13. A composition for use according to any one of the preceding items, wherein the composition further comprises at least one antimicrobial compound.
[0300] Item 14. A composition for use according to Item 13, wherein the at least one antimicrobial compound is nanosilver, penicillin, ofloxacin, tetracycline, aminoglycosides, erythromycin, gentamycin, flucloxacillin, clarithromycin, doxycycline, gentamicin, metronidazole, zole), co-amoxiclav, co-trimoxazole (in penicillin), ceftriaxone, piperacillin with tazobactam, clindamycin, ciprofloxacin, vancomycin, teicoplanin, linezolid, and / or standard of care antimicrobial agents, or any combination thereof.
[0301] Item 15. The composition for use according to any one of the preceding items, wherein the jellyfish collagen is formulated for topical application to a wound.
[0302] Item 16. The composition for use according to any one of the preceding items, wherein the collagen is administered at a dose of 0.01 g / L to 200 g / L, preferably 1 g / L to 50 g / L per administration.
[0303] Item 17. A composition for use according to any one of the preceding items, formulated as a cream, a double gel, an ointment, a mask, a serum, a milk, a lotion, a paste, a foam, an aerosol, a stick, a shampoo, a conditioner, a patch, a hydroalcoholic or oily aqueous solution, an oil-in-water or water-in-oil or multiple emulsions, an aqueous or oily gel, a liquid, a paste or a solid anhydrous product, an electrospun collagen nanofibrous matrix, a membrane and / or an oil dispersion using spheres in an aqueous phase, which spheres are polymer nanoparticles, such as nanospheres and nanocapsules or lipid vesicles of ionic and / or non-ionic type, more preferably an electrospun collagen nanofibrous matrix and / or a membrane.
[0304] Item 18. A composition for use according to any one of the preceding items, wherein the jellyfish collagen further comprises a pharmaceutically acceptable excipient and / or carrier and / or a pharmaceutically active ingredient.
[0305] Item 19. The composition for use according to Item 18, wherein the pharmaceutically active ingredient is lidocaine, preferably at a concentration of 0.1% to 2%.
[0306] Item 20. A composition for use according to any one of the preceding items, wherein the wound to be treated is a pressure sore, a graft site, a surgical wound, an ulcer, preferably a diabetic ulcer, a thermal burn, a chemical burn, an electrical burn, a laceration, an abrasion, a puncture wound, an avulsion, a seroma and / or a hematoma.
[0307] Item 21. The composition for use according to any one of the preceding items, wherein the jellyfish collagen is in the form of a micronized powder.
[0308] Item 22. The composition for use according to Item 21, wherein the micronized powder has a particle size of 1 μm to 1000 μm, preferably wherein the micronized powder has a particle size of 200 μm to 500 μm.
[0309] Item 23. A composition for use according to any one of items 1 to 20, wherein the jellyfish collagen is in the form of a collagen 3D sponge scaffold.
[0310] Item 24. A composition for use according to any of the preceding items, wherein the composition promotes improved angiogenesis in treated wounds, optionally wherein the improved angiogenesis is relative to untreated wounds and / or wounds treated with bovine collagen.
[0311] Item 25. A method for producing the jellyfish collagen according to Item 1, the method comprising at least the following steps:
[0312] i) extracting acid-soluble collagen from a jellyfish collagen source; and
[0313] ii) purifying the jellyfish collagen to provide a purified jellyfish collagen solution.
[0314] Item 26. The method for producing jellyfish collagen according to Item 25, wherein the method further comprises the following steps:
[0315] iii). Adding a cross-linking agent to form cross-linked jellyfish collagen.
[0316] Item 27. The method for producing jellyfish collagen according to Item 26, wherein the cross-linking agent is EDC, Genipin or polyethylene glycol (PEG).
[0317] Item 28. The method for producing jellyfish collagen according to Item 27, wherein the cross-linking agent is EDC, optionally wherein the concentration of the EDC is 0.01% to 5%, preferably wherein the concentration of the EDC is 0.5% to 1%.
[0318] Item 29. A method for producing jellyfish collagen according to any one of Items 25 to 28, wherein the method further comprises digesting the extracted jellyfish collagen with a peptidase to provide atelo-jellyfish collagen, optionally wherein the peptidase is pepsin.
[0319] Item 30. The method for producing jellyfish collagen according to Item 29, wherein the step of digesting the collagen with a peptidase is performed after the extraction step and before the purification step.
Claims
1. Use of a composition for preparing a medicament for treating a wound, wherein the composition comprises jellyfish collagen, wherein the jellyfish collagen is in the form of a micronized powder.
2. The use according to claim 1, wherein the jellyfish collagen is cross-linked.
3. The use according to claim 1, wherein the jellyfish collagen is non-cross-linked.
4. The use according to claim 1, wherein the jellyfish collagen is in the form of its atelopeptide.
5. The use according to claim 1, wherein the jellyfish collagen is in the form of its telopeptide. The use according to claim 1 , wherein the jellyfish collagen is thiolated.
7. The use according to claim 1, wherein the jellyfish collagen is derived from the subphylum Scyphozoa.
8. The use according to claim 7, wherein the source of the jellyfish collagen is selected from the group consisting of: Rhizostomas pulmo, Rhopilema esculentum, Rhopilemanomadica, Stomolophus meleagris, Aurelia sp., Cassiopea andromeda, Nemopilema nomurai or any combination thereof.
9. The use according to claim 1, wherein the composition further comprises at least one growth factor.
10. The use according to claim 9, wherein the at least one growth factor is platelet-rich plasma (PRP), epidermal growth factor 38 (EGF), transforming growth factor-β (TGF-B, TGF-B2, TGF-B3), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), granulocyte-monocyte colony-stimulating growth factor, platelet-derived growth factor, insulin-like growth factor 1 (IGF1), basic fibroblast growth factor (bFGF) and / or vascular endothelial growth factor (VEGF) or any combination thereof.
11. The use according to claim 1, wherein the composition further comprises at least one antimicrobial compound.
12. The use according to claim 11, wherein the at least one antimicrobial compound is nanosilver, penicillin, ofloxacin, tetracycline, aminoglycosides, erythromycin, gentamycin, flucloxacillin, clarithromycin, doxycycline, gentamicin, metronidazole, co-amoxiclav, co-trimoxazole (in penicillin), ceftriaxone, piperacillin and tazobactam, clindamycin, ciprofloxacin, vancomycin, teicoplanin, linezolid and / or standard of care antimicrobial agents or any combination thereof.
13. The use according to claim 1, wherein the jellyfish collagen is formulated for topical application to wounds.
14. The use according to claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient and / or carrier and / or a pharmaceutically active ingredient.
15. The use according to claim 14, wherein the pharmaceutically active ingredient is lidocaine.
16. The use according to claim 1, wherein the wound to be treated is a pressure sore, a graft site, a surgical wound, an ulcer, a thermal burn, a chemical burn, an electrical burn, a laceration, an abrasion, a puncture wound, an avulsion, a seroma and / or a hematoma.
17. Use according to claim 16, wherein the wound to be treated is a diabetic ulcer.
18. The use according to claim 1, wherein the micronized powder has a particle size of 1 μm to 1000 μm.
19. Use according to claim 18, wherein the micronized powder has a particle size of 200 to 500 μm.
20. The use of claim 1, wherein the composition promotes improved angiogenesis in treated wounds, wherein the improved angiogenesis is relative to untreated wounds and / or wounds treated with bovine collagen.
